Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.

Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page
- Check4 days agoChange DetectedA new version of the study record was added, submitted on 2026-10-15 and posted on 2026-10-16, with a change to the study status.SummaryDifference0.4%

- Check11 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedA new revision entry v3.7.0 was added to the study record history, and the previous revision v3.6.6 was removed, indicating an update to the history log's versioning metadata. This change does not alter study data or core content.SummaryDifference0.1%

- Check46 days agoChange DetectedThe record history shows an update to recruitment status, indicating the trial is active but not currently enrolling participants. This signals that enrollment is not open at this time.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page's revision version was updated from v3.6.5 to v3.6.6, indicating a minor system update to the record history.SummaryDifference0.1%

- Check75 days agoChange DetectedA new revision entry (v3.6.5) has been added to the history, indicating a recent update to the page. The previous revision (v3.6.4) is listed under deletions, suggesting it is no longer part of the current change set.SummaryDifference0.1%

Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.